NOTE: Apologies for the delayed post release. 22″ of October snow yielded a slow start to the day… Waltham, MA-based Synageva Biopharma (formerly AviGenics) is focused on novel, next-generation and follow-on protein therapeutics that leverage their Synageva Expression Platform (SEP™). SEP™ is an integrated platform of proprietary vectors and protein production, processing and purification systems [...]

• 561http://clsdf.com/2009/10/synageva-biopharma-series-c-45m/Synageva+BioPharma+%7C+Series+C+%2445M2009-10-29+17%3A55%3A15admin

GlobeImmune, Inc. closed a $41.2MM Series C financing. The round was led by Wexford Capital, other participants include Celgene (NASDAQ: CELG), Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital Corp., Boston Life Science Venture, and WRF Capital. Previous investors who participated in the round include HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, [...]

• 222http://clsdf.com/2007/09/globeimmune-series-c-41-2mm/GlobeImmune%3A+Series+C+%2441.2MM2007-09-27+04%3A09%3A00admin